AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock

RecruitingNAAges 18 Years - anyAllCMC Ambroise Paré
💬

In plain words

What the trial is, and whether it could suit you

Cardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion. Central venous pressure (CVP) can help assess effective perfusion pressure. This study investigates whether a personalized MAP target adjusted by CVP improves organ function and survival compared to standard MAP management.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Aged ≥18 years * Cardiogenic shock state, according to the consensus definition, * SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C * Consent from the patient or close relative / trusted person or emergency inclusion procedure * Benefiting fromciary of a social security scheme Exclusion Criteria: * Catecholamine infusion for more than 24 consecutive hours; * CVP \< 5 mm Hg at inclusion; * MAP \> 70 mmHg at inclusion; * Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml/min/1.73 m²) or G5 (defined by an eGFR less than 15 ml/min/1.73 m²) according to the KDIGO CKD classification at inclusion; * Chronic dialysis or presence of renal replacement therapy criteria at inclusion ; * Recovered cardiopulmonary arrest within 7 days prior to inclusion; * Patient already on mechanical circulatory support at inclusion before enrollment (patients who receive support after inclusion will not be excluded); * Primary diagnosis of tamponade, pulmonary embolism, or septic shock; * Hypersensitivity to norepinephrine tartrate or to any of the following excipients: sodium chloride, hydrochloric acid or sodium hydroxide water for injectable preparations; * Absence of central venous access; * Known pregnancy or current breastfeeding; * Under legal guardianship, curatorship, or judicial protection.
💊

What it tests

  • Personalized MAP
  • Standard MAP
📍

Where

11 sites
CHU d'Amiens-Picardie
Amiens, France
Hôpital Henri Mondor
Créteil, France
Hôpital Privé Jacques Cartier
Massy, France
CMC Ambroise Paré - Hartmann
Neuilly-sur-Seine, France
CHU d'Orléans
Orléans, France
Hôpital Lariboisière
Paris, France
Hôpital Cochin
Paris, France
Clinique NCT + /Saint-Gatien
Saint-Cyr-sur-Loire, France

…and 3 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy